Aardvark Therapeutics shares slumped 54% pre-market after voluntarily pausing its Phase 3 HERO trial due to cardiac effects found in a healthy volunteer. Analysts downgraded the stock, citing added uncertainty. The company no longer expects to release topline data in Q3 2026, delaying the study's timeline for treating Prader-Willi syndrome.